#1 Clinical Trials Search in Europe

Study on Dapagliflozin for Patients with Chronic Right Heart Failure

2 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called dapagliflozin in patients with chronic right heart failure. Chronic right heart failure is a condition where the right side of the heart has difficulty pumping blood effectively, which can lead to symptoms like swelling and shortness of breath. The study aims to determine if dapagliflozin, when added to the usual care, is more effective in improving the condition compared to the usual care plus a placebo.

Participants in the study will receive either dapagliflozin or a placebo, both taken as oral tablets. The treatment period will last for about three months. Throughout the study, changes in certain health markers will be monitored, such as the levels of a specific protein in the blood that indicates heart stress, known as NT-proBNP. Additionally, the study will assess changes in the participants’ quality of life, heart function, and exercise capacity.

The goal of the study is to see if dapagliflozin can help reduce the symptoms and improve the overall health of people with chronic right heart failure. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for this condition in the future.

1 joining the study

Upon joining the study, the patient will provide written informed consent, confirming their willingness and ability to participate.

Eligibility criteria include being between 18 and 89 years old and having chronic right heart failure, as defined by specific medical assessments.

2 initial assessment

The patient will undergo initial assessments to confirm the presence of right heart failure. This includes tests like echocardiography to measure heart function and blood tests to check levels of NT-proBNP, a marker of heart failure.

3 medication administration

The patient will receive either dapagliflozin or a placebo. Dapagliflozin is taken orally, and the specific dosage and frequency will be determined by the study protocol.

The medication is administered alongside the standard care for right heart failure.

4 ongoing monitoring

Throughout the study, the patient’s health and response to the medication will be monitored regularly. This includes checking NT-proBNP levels, heart function through cardiac MRI, and exercise capacity via a 6-minute walking test.

Quality of life will be assessed using the Kansas City Cardiomyopathy Questionnaire.

5 end of treatment evaluation

At the end of the treatment period, the patient will undergo final assessments to evaluate changes in NT-proBNP levels, heart function, exercise capacity, and quality of life.

The study aims to determine if dapagliflozin is more effective than a placebo in improving these outcomes.

Who Can Join the Study?

  • The patient must be willing and able to participate and provide written consent.
  • The patient must be between 18 and 89 years old.
  • The patient must have chronic right heart failure. This means the right side of the heart is not working well. Specific signs include:
    • Reduced right ventricular systolic function or RV strain. This can be shown by:
      • Tricuspid annular plane systolic excursion (TAPSE) less than 16 mm. TAPSE is a measure of how well the right side of the heart is pumping.
      • RV fractional area change (FAC) less than 35%. FAC is another measure of heart pumping ability.
      • Systolic pulmonary artery pressure (PAP sys) of 35 mmHg or more, along with a large inferior vena cava (a big vein) that doesn’t collapse much when you breathe in.
    • N-terminal pro-BNP (NT-proBNP) greater than 125 pg/ml. This is a blood test that shows heart stress.
    • Signs of right heart congestion, like swelling (edema), a large inferior vena cava, or fluid around the lungs, or needing medicine to prevent these signs.
  • For women who can have children (until one year after menopause):
    • A negative pregnancy test is required.
    • Use of highly effective birth control methods during treatment and for 5 days after stopping the study drug.

Who Cannot Join the Study?

  • Patients who do not have chronic right heart failure cannot participate. This means the study is only for those with a long-term condition affecting the right side of the heart.
  • Patients who are not within the specified age range cannot participate. The study is for certain age groups only.
  • Patients who are part of a vulnerable population cannot participate. This means people who might need special protection or care are not included.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Universitaetsmedizin Goettingen Goettingen Germany

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Recruiting
02.08.2024

Trial locations

Investigated drugs:

Dapagliflozin is a medication used in this trial to help treat patients with chronic right heart failure. It is being tested to see if it can improve heart function and reduce symptoms when added to the usual treatments that patients are already receiving. The goal is to determine if dapagliflozin can provide better outcomes for patients compared to the standard treatments alone.

Investigated diseases:

Chronic Right Heart Failure – This condition occurs when the right side of the heart is unable to pump blood effectively, leading to a buildup of blood in the veins. Over time, this can cause swelling in the legs and abdomen due to fluid retention. The heart’s reduced ability to pump blood can also lead to fatigue and shortness of breath. As the condition progresses, the heart may become enlarged, and the symptoms can worsen. The disease often develops gradually and can be influenced by other heart or lung conditions. It requires ongoing management to address the symptoms and prevent further complications.

Trial ID:
2024-515044-23-01
Protocol code:
2021-01755
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia Denmark Hungary Latvia +6